Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Nordimet 10mg/0.4ml solution for injection pre-filled pens
0801030P0BFABFN
|
Nordimet | Methotrexate | Malignant Disease and Immunosuppression | 993 |
|
Mycophenolate mofetil 1g/5ml oral suspension sugar free
0802010M0AAAJAJ
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 978 |
|
CellCept 250mg capsules
0802010M0BBAAAA
|
CellCept | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 965 |
|
Mycophenolic acid 360mg gastro-resistant tablets
0802010N0AAABAB
|
Mycophenolic sodium | Mycophenolic sodium | Malignant Disease and Immunosuppression | 937 |
|
Triptorelin embonate 22.5mg inj vials
0803042S0AAABAB
|
Triptorelin embonate | Triptorelin embonate | Malignant Disease and Immunosuppression | 923 |
|
Aromasin 25mg tablets
0803041C0BBAAAA
|
Aromasin | Exemestane | Malignant Disease and Immunosuppression | 916 |
|
Calcium folinate 15mg tablets
0801000I0AAAHAH
|
Calcium folinate (Antimetabolite) | Calcium folinate | Malignant Disease and Immunosuppression | 899 |
|
Advagraf 5mg modified-release capsules
0802020T0BCACAP
|
Advagraf | Tacrolimus | Malignant Disease and Immunosuppression | 863 |
|
Tamoxifen 10mg/5ml oral solution sugar free
0803041S0AAAJAJ
|
Tamoxifen citrate | Tamoxifen citrate | Malignant Disease and Immunosuppression | 795 |
|
Hydrea 500mg capsules
0801050P0BBAAAA
|
Hydrea | Hydroxycarbamide | Malignant Disease and Immunosuppression | 780 |
|
Sirolimus 1mg tablets
0802020U0AAADAD
|
Sirolimus | Sirolimus | Malignant Disease and Immunosuppression | 745 |
|
Azathioprine 75mg tablets
0802010G0AACMCM
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 739 |
|
Imuran 25mg tablets
0802010G0BCAAAD
|
Imuran | Azathioprine | Malignant Disease and Immunosuppression | 730 |
|
Adoport 5mg capsules
0802020T0BEABAA
|
Adoport | Tacrolimus | Malignant Disease and Immunosuppression | 690 |
|
Myfortic 360mg gastro-resistant tablets
0802010N0BBABAB
|
Myfortic | Mycophenolic sodium | Malignant Disease and Immunosuppression | 644 |
|
Myfenax 500mg tablets
0802010M0BCAAAB
|
Myfenax | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 590 |
|
Provera 100mg tablets
0803020H0BDAAAC
|
Provera (Cancer) | Medroxyprogesterone acetate | Malignant Disease and Immunosuppression | 586 |
|
Nordimet 12.5mg/0.5ml solution for injection pre-filled pens
0801030P0BFACFP
|
Nordimet | Methotrexate | Malignant Disease and Immunosuppression | 576 |
|
Advagraf 0.5mg modified-release capsules
0802020T0BCAAAM
|
Advagraf | Tacrolimus | Malignant Disease and Immunosuppression | 570 |
|
Nordimet 17.5mg/0.7ml solution for injection pre-filled pens
0801030P0BFAEFR
|
Nordimet | Methotrexate | Malignant Disease and Immunosuppression | 546 |
|
Staladex 11.25mg implant pre-filled syringes
0803042N0BDAAAF
|
Staladex | Leuprorelin acetate | Malignant Disease and Immunosuppression | 546 |
|
Provera 200mg tablets
0803020H0BDACAD
|
Provera (Cancer) | Medroxyprogesterone acetate | Malignant Disease and Immunosuppression | 500 |
|
Medroxyprogesterone 400mg tablets
0803020H0AAAFAF
|
Medroxyprogest acetate (Cancer) | Medroxyprogesterone acetate | Malignant Disease and Immunosuppression | 490 |
|
Methotrexate 20mg/0.8ml inj pre-filled disposable devices
0801030P0AAFSFS
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 487 |
|
Ciclosporin 50mg capsules
0802020G0AAAFAF
|
Ciclosporin (Systemic) | Ciclosporin | Malignant Disease and Immunosuppression | 466 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.